+86-28-82633987
ISO ISO
ISO 17025 ISO 17025
usp usp
EN
CN EN

Hepatitis C

Catalog No Product Description CAS No. Purity Structural Formula
BPF0598
Trachelogenin
Trachelogenin has antiproliferative effect, the mechanism is related to affect the phosphorylation of key proteins such as β-Catenin, c-Myc and GSK3 in the β-Catenin signaling pathway in a concentration-dependent manner.
34209-69-3 98% Trachelogenin
BP0965
Mulberroside C
Mulberroside C shows weak activity (IC 50 =75.4 μg/ml) against herpes simplex type 1 virus (HSV-1).
102841-43-0 98% Mulberroside C
BP4904
Dehydrojuncusol
Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.
117824-04-1 98% Dehydrojuncusol
BP2129 50886-61-8 98% Isoeuphorbetin
BP1240
Saikosaponin B2
Saikosaponin b2 is a saikosaponin.
58316-41-9 98% Saikosaponin B2
SBP03340
Ladanein
Ladanein is a dimethoxyflavone that is scutellarein in which the hydroxy groups at positions 4' and 7 are replaced by methoxy groups. It is an effective anti-HCV agent. It has a role as an antiviral agent, a radical scavenger and a plant metabolite. It is a dimethoxyflavone and a dihydroxyflavone. It is functionally related to a scutellarein. Ladanein is a phytochemicals inhibitor that is known to disrupt the interactions of core and other hepatitis C virus (HCV) proteins.Ladanein possesses free radicals DPPH and ABTS +.scavenging activity, it also displays moderate (20-40 microM) activities against K562, K562R (imatinib-resistant), and 697 human leukemia cell lines.
10176-71-3 98% Ladanein
BP3866
Platycodin D3
Platycodin D3 is a NF-κB inhibitor, it could as expectorants in diverse inflammatory pulmonary diseases, it can regulate the production and secretion of airway mucin; it can significantly enhance mitogen- and OVA-induced splenocyte proliferation in the OVA-immunized mice. Platycodin D3 also exerts anti-Hepatitis C virus (HCV) activity.
67884-03-1 98% Platycodin D3
BP1291
Sennidin B
Sennidin B stimulates glucose incorporation in rat adipocytes.
517-44-2 98% Sennidin B
BP1241
Saikosaponin C
Saikosaponin C exhibits anti-HBV activity, it has the potential for therapeutic angiogenesis but is not suitable for cancer therapy, it also might be a novel therapeutic tool for treating human AD and other neurodegenerative diseases. It inhibited caspase-3 activation and caspase-3-mediated-FAK degradation, induced matrix metalloproteinase-2 (MMP-2)、vascular endothelial growth factor (VEGF) 、the p42/p44 mitogen-activated protein kinase (MAPK, ERK). Saikosaponin C is a member of the class of saikosaponins that is saikogenin E substituted by a 6-deoxy-alpha-L-mannopyranosyl-(14)-[beta-D-glucopyranosyl-(16)]-beta-D-glucopyranosyl group at position 3beta. It is a natural product isolated from the traditional Chinese herb, Radix Bupleuri and exhibits anti-HBV replication activity. It has a role as an anti-HBV agent and a plant metabolite.
20736-08-7 98% Saikosaponin C
BP1290
Sennidin A
Sennidin A, has two hydroxyanthraquinone-like moieties, exerts inhibition on NS3 helicase with IC50 values of 0.8 uM. Sennidin A in combination with necrosis inducing drugs/therapies may generate synergetic tumoricidal effects on solid malignancies by means of primary debulking and secondary cleansing process. It stimulates glucose incorporation in the phosphatidylinositol 3-kinase (PI3K)- and Akt-dependent in rat adipocytes, but in the IR/IRS1-independent manner.
641-12-3 98% Sennidin A